menu
    • menu
    [{"orgOrder":0,"company":"Ocelot Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"OCE-205","moa":"V1 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Ocelot Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ocelot Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ocelot Bio \/ Inapplicable"},{"orgOrder":0,"company":"Ocelot Bio","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Series A Financing","leadProduct":"OCE-205","moa":"V1 receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Ocelot Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ocelot Bio \/ RA Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"Ocelot Bio \/ RA Capital Management"},{"orgOrder":0,"company":"Ocelot Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"OCE-205","moa":"V1 receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Ocelot Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ocelot Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocelot Bio \/ Inapplicable"},{"orgOrder":0,"company":"Ocelot Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"OCE-205","moa":"V1 receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Ocelot Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ocelot Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocelot Bio \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Ocelot Bio

    Menu

    Ocelot Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ocelot Bio

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed

                            Ocelot Bio

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OCE-205

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ocelot Bio Receives FDA Orphan Drug Designation for OCE-205 for the Treatment of Ascites

                            Details : OCE-205 is a therapeutic peptide with a differentiated mechanism of action. It is being evaluated in preclinical studies for the treatment of Ascites due to all etiologies except cancer.

                            Product Name : OCE-205

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            December 20, 2023

                            Lead Product(s) : OCE-205

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ocelot Bio

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed

                            Ocelot Bio

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OCE-205

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ocelot Bio to Present Data Highlighting Pharmacodynamic Activity and Safety of OCE-205 at AASLD The Liver Meet...

                            Details : OCE-205 is a mixed agonist-antagonist therapeutic peptide that has a mechanism of action designed to selectively target consequences of the systemic hemodynamic complications associated with decompensated liver cirrhosis, or ESLD.

                            Product Name : OCE-205

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            October 24, 2022

                            Lead Product(s) : OCE-205

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ocelot Bio

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed

                            Ocelot Bio

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OCE-205

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ocelot Bio Receives FDA Orphan Drug Designation for OCE-205 for the Treatment of Hepatorenal Syndrome

                            Details : OCE-205 is a peptide therapeutic with a differentiated mechanism of action (MOA) designed to selectively target serious hemodynamic complications that are the result of liver fibrosis and portal hypertension in ESLD.

                            Product Name : OCE-205

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            August 22, 2022

                            Lead Product(s) : OCE-205

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Ocelot Bio

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed

                            Ocelot Bio

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OCE-205

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I

                            Sponsor : RA Capital Management

                            Deal Size : $36.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Ocelot Bio Closes $36 Million Series A Financing, Appoints Katherine Vega Stultz as President and Chief Execut...

                            Details : Proceeds will be used for lead clinical candidate, OCE-205, a peptide therapeutic with a mechanism of action designed to selectively target complications of portal hypertension that is being explored first in HRS-AKI.

                            Product Name : OCE-205

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            March 23, 2022

                            Lead Product(s) : OCE-205

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I

                            Sponsor : RA Capital Management

                            Deal Size : $36.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth